Gout & crystal arthritis

Canakinumab's Effect Against Subsequent Gout Flares and High‐Sensitivity C‐Reactive Protein Levels: A Causal Mediation Analysis

Arthritis Care Res (Hoboken)Published Secondary analysis of the CANTOS randomised trial

Primary result · Gout flare, overall cohortResult — go to the resultHazard ratio 0.50 95% CI 0.37–0.68

Authors' conclusion

The first 3-month reduction in hsCRP level was not a good biomarker for canakinumab's protective effect on future gout flares in the overall cohort.

Study context

Population
Canakinumab Anti-Inflammatory Thrombosis Outcome Study participants, overall and stratified by prevalent gout at baseline9,221 without and 747 with prevalent gout
Comparison
Canakinumab vs placebo; mediation through 3-month change in log high-sensitivity C-reactive protein (hsCRP)
Primary endpoint
Gout flares; proportion of canakinumab's effect mediated by 3-month change in log hsCRP
Methodological detailspost hoc, causal mediation analysis, Cox or Weibull regression, stratified by prevalent gout at baseline
  • Post hoc
  • Causal mediation analysis
  • Cox or Weibull regression
  • Stratified by prevalent gout at baseline

Primary result

Gout flare, overall cohort

Hazard ratio

0.50

95% CI 0.37–0.68

Canakinumabvs Placebo
HR 0.50 (95% CI 0.37–0.68)

As reported in the abstract

Proportion explained by mediated effect through hsCRP reduction in first 3 months
6%

Further findings

OutcomeHR (95% CI)
Gout flare, prevalent-gout subgroup0.58 (0.36–0.95)
Gout flare, prevalent-gout subgroup — Proportion explained by mediated effect through hsCRP reduction
31%
Gout flare, prevalent-gout subgroup — Proportion mediated, Weibull analysis
47%

Gout flare, subgroup without prevalent gout

Indirect effect via hsCRP reductions unclear

Original publication

Canakinumab's Effect Against Subsequent Gout Flares and High‐Sensitivity C‐Reactive Protein Levels: A Causal Mediation Analysis. Arthritis Care Res (Hoboken). Published 26 November 2022. doi:10.1002/acr.24832

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.